IKF Pneumologie GmbH & Co. KG

At IKF Pneumologie GmbH & Co. KG in Frankfurt, a major share of the clinical research focuses on respiratory tract diseases, especially asthma and chronic obstructive pulmonary disease. These studies are largely aimed at testing new treatments and improving control of symptoms, flare-ups, and long-term breathing function.

• Severe, uncontrolled, and eosinophilic asthma
• Chronic obstructive pulmonary disease and chronic bronchitis
• Evaluating new therapies to reduce exacerbations and improve disease control

The site is also involved in research on treatment effectiveness in people who have not responded well to current inhaled or biologic therapies.

Another important area at this German research site is bronchiectasis, including forms linked to chronic Pseudomonas aeruginosa colonization. These trials are designed to better understand how to reduce lung infections, limit exacerbations, and improve day-to-day respiratory health.

• Non-cystic fibrosis bronchiectasis
• Bronchiectasis with chronic bacterial colonization
• Testing therapies to lower exacerbation rates and improve lung outcomes

Research in this field reflects a strong interest in managing difficult-to-treat airway disease and chronic inflammation.

The portfolio also includes studies in congenital, hereditary, and neonatal diseases, with a focus on rare conditions such as ataxia telangiectasia and cystic fibrosis. These trials aim to evaluate new approaches that may improve safety, neurological symptoms, or lung function in patients with limited treatment options.

• Ataxia telangiectasia and related neurological symptoms
• Cystic fibrosis and inherited lung disease
• Assessing safety and potential clinical benefit of emerging therapies

This area highlights the site’s role in research for rare diseases where evidence-based treatment choices are still limited.

Otorhinolaryngologic diseases are another key focus, including chronic rhinosinusitis with nasal polyps and perennial allergic rhinitis. The trials in this area are mainly evaluating whether new therapies can ease nasal symptoms, reduce congestion, and improve overall quality of life.

• Chronic rhinosinusitis with nasal polyps
• Perennial allergic rhinitis
• Improving symptom relief and patient-reported outcomes

This research complements the site’s broader airway portfolio by addressing both lower and upper respiratory disease.

The site also conducts research in idiopathic pulmonary fibrosis and other chronic lung conditions where preserving lung function is a major goal. These studies are focused on measuring whether new treatments can slow decline, improve breathing capacity, and support better long-term outcomes.

• Idiopathic pulmonary fibrosis
• Chronic structural lung disease and reduced lung capacity
• Evaluating treatment effects on lung function and disease progression

This work adds an important fibrotic lung disease dimension to the site’s mainly airway-centered research program.

Beyond chronic lung disease, the trial mix includes studies in virus diseases such as influenza, along with selected work in nutritional and metabolic diseases such as obesity. These projects are generally intended to assess prevention, safety, or broader health effects in relevant patient groups.

• Influenza and respiratory viral prevention research
• Obesity and related cardiometabolic risk
• Supporting studies that broaden the site’s clinical research scope

Overall, the portfolio shows a strong emphasis on respiratory medicine with additional coverage of rare disease and broader internal medicine topics.